Frontlight ResearchEarly access
Crohn's disease trials in United States
96 of 125 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Charleston, Cleveland, Detroit, Hershey, Loma Linda, Morristown, New York, Oklahoma City, Orange, Park Ridge, Phoenix, Tacoma
- Age
- 2 years to 17 years
- People
- 70 worldwide
- Run by
- Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00 - No phaseEnrolling by invitationImproving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
- Where
- Atlanta, Boston, Chapel Hill, Charlotte, Lake Success, Philadelphia, San Diego, San Francisco, Scottsdale
- Age
- 13 years and over
- People
- 900
- Run by
- University of North Carolina, Chapel Hill
See details and how to joinNCT06424769 - No phaseEnrolling by invitationPartial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
- Where
- Austin, Beverly Hills, Birmingham, Chapel Hill, New Brunswick, New Haven, Philadelphia
- Age
- 18 years to 80 years
- People
- 80
- Run by
- James Lewis
See details and how to joinNCT07356232 - No phaseEnrolling by invitationOnline Pain Education for Crohn's Disease and Ulcerative Colitis
- Where
- Los Angeles
- Age
- 18 years and over
- People
- 60
- Run by
- Cedars-Sinai Medical Center
See details and how to joinNCT07671313 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Where
- Anaheim, Ann Arbor, Atlanta, Aurora, Bellevue, Bethesda, Boston, Chapel Hill, Charlotte, Chicago, Clearwater, Clinton Township, Clive, Colorado Springs, Coronado, Dallas, Decatur, Denton, Dothan, Englewood, Evanston, Fort Myers, Great Neck, Gurnee, Hackensack, Hamden, Hershey, Houston, Indianapolis, Inverness, Kansas City, Lakewood, Lancaster, Liberty, Little Rock, Los Angeles, Louisville, Lubbock, Macon, Mansfield, Margate, Mentor, Miami, Middletown, Nashville, New Haven, New York, Oklahoma City, Orange, Orlando, Oxnard, Philadelphia, Phoenix, Port Jefferson, Providence, Richmond, Rochester, San Antonio, San Diego, Seattle, Sioux Falls, Southlake, St Louis, Sun City, Tacoma, Tampa, Topeka, Tucson, Tyler, Uniontown, University Park, Valencia, Washington D.C., Zachary
- Age
- 16 years to 80 years
- People
- 1,200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00 - No phaseNot yet taking people in United StatesDigital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease
- Where
- The Bronx
- Age
- 18 years and over
- People
- 40
- Run by
- Montefiore Medical Center
See details and how to joinNCT06510296 - Phase 3Taking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Arlington, Atlanta, Beavercreek, Boston, Brooksville, Brunswick, Charleston, Charlotte, Chesapeake, Chicago, Cincinnati, Clearwater, Cleveland, Columbus, Coral Gables, Crestview Hills, Dothan, El Paso, Farmington Hills, Fuquay-Varina, Garden Grove, Georgetown, Germantown, Glenview, Greenville, Gurnee, Harlingen, Hershey, Hialeah, Houston, Idaho Falls, Indianapolis, Inglewood, Kissimmee, La Jolla, Lakewood Rch, Lancaster, Lansdowne Town Center, Liberty Township, Littleton, Lone Tree, Los Alamitos, Louisville, Lynchburg, Macon, Mansfield, Mesquite, Miami, Monroe, Nashville, New Albany, New York, Norman, North Las Vegas, North Massapequa, Orlando, Oxford, Phoenix, Providence, Queens Village, Richmond Hill, Roanoke, Rochester, San Antonio, San Diego, San Francisco, Seattle, Southaven, Southlake, Sun City, Tampa, Temple, Temple Terrace, Tucson, Tyler, Uniontown, Vancouver, Westlake, Weston, Wichita, Williamsburg, Zephyrhills
- Age
- 16 years to 80 years
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - Phase 1Taking peopleTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Where
- Atlanta, Baltimore, Bethesda, Birmingham, Boston, Chicago, City of Saint Peters, Columbus, Creve Coeur, Dallas, Detroit, Fairway, Fort Worth, Hays, Houston, Kansas City, Lawrence, Lee's Summit, Lexington, Mineola, New Brunswick, New Haven, New York, North Kansas City, Olathe, Overland Park, Palo Alto, Philadelphia, Pittsburg, Pittsburgh, Richardson, Richmond, Sacramento, Salina, Salt Lake City, St Louis, Topeka, Washington D.C., Westwood
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT03816345 - Phase 2Taking peopleA Study of SL-325 in Crohn's Disease Patients
- Where
- Boston, Cincinnati, Columbus, Glen Burnie, Houma, Inverness, Kansas City, Kissimmee, Liberty, Little Rock, Marrero, Maspeth, Naples, Nashville, Orlando, Oxnard, St Louis, Tampa, Temple City, West Hills
- Age
- 18 years to 80 years
- People
- 232
- Run by
- Shattuck Labs, Inc.
See details and how to joinNCT07753850 - Phase 3Taking peopleExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Where
- Bristol, Charlottesville, Garland, Liberty, Lubbock, New York, San Antonio, Southlake, Tacoma, Tyler, Ypsilanti
- Age
- 18 years and over
- People
- 1,380 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06651281 · EU 2024-513533-20-00 - Phase 4Taking peopleIron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's Disease
- Where
- New York
- Age
- 3 years to 21 years
- People
- 150
- Run by
- Weill Medical College of Cornell University
See details and how to joinNCT07925450 - Phase 2Not yet taking people in United StatesOral N-acetylglucosamine in Crohn's Disease
- Where
- Baltimore
- Age
- 18 years to 80 years
- People
- 40
- Run by
- Johns Hopkins University
See details and how to joinNCT07225998 - Phase 3Taking peopleA Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
- Where
- Harlingen, New York
- Age
- 2 years to 17 years
- People
- 100 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07298421 · EU 2025-523318-96-00 - Phase 2Taking peopleA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Where
- Atlanta, Bridgeton, Cedar Park, Colorado Springs, Denton, Fayetteville, High Point, Houma, Houston, Johnson City, Kissimmee, Lancaster, Lewisville, Lynchburg, Mansfield, Miami, North Las Vegas, Ogden, Orlando, Palmetto Bay, Raleigh, San Diego, Summerville, Tyler
- Age
- 18 years to 85 years
- People
- 385 worldwide
- Run by
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00 - Phase 3Taking peopleMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Where
- Anaheim, Beverly Hills, Chevy Chase, Chicago, Cordova, Dothan, Fayetteville, Greenville, Idaho Falls, Indianapolis, Lebanon, Los Alamitos, Louisville, Miami, Milwaukee, New Albany, New Bedford, New Iberia, New York, Northridge, Orlando, Pensacola, Philadelphia, Providence, San Antonio, Shreveport, St Louis, Sunrise, Tacoma, Tyler, Westlake, Yonkers
- Age
- 18 years to 70 years
- People
- 290 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00 - Phase 2Taking peopleA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Where
- Atlanta, Chicago, Englewood, Kingwood, Las Vegas, Los Angeles, Miami, Miami Lakes, Oxnard, San Antonio, Scottsdale, St Louis, Topeka, Wyoming
- Age
- 18 years to 80 years
- People
- 60 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00 - Phase 2Taking peopleA Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Where
- Atlanta, Chicago, Englewood, Kingwood, Las Vegas, Los Angeles, Miami, Miami Lakes, Oxnard, San Antonio, Scottsdale, St Louis, Topeka, Wyoming
- Age
- 18 years to 80 years
- People
- 60 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07483099 - Phase 3Taking peopleA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Atlanta, Boston, Colchester, Dayton, Fort Worth, Hartford, Indianapolis, Los Angeles, Morristown, New York, Philadelphia
- Age
- 2 years to 17 years
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00 - Phase 3Taking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Atlanta, Cincinnati, Fort Worth, Indianapolis, Salt Lake City
- Age
- 3 years to 64 years
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - Phase 2/3Taking peopleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Anaheim, Atlanta, Austin, Canoga Park, Carmel, Carrollton, Chandler, Chapel Hill, Charleston, Charlotte, Chesapeake, Chevy Chase, Colorado Springs, Coronado, Crestview Hills, Cutler Bay, Dallas, Danbury, Glen Burnie, Harrisburg, Hershey, Houston, Indianapolis, Inverness, Jacksonville, Lafayette, Lakewood Rch, Lancaster, Litchfield Park, Los Angeles, Louisville, Lynchburg, Macon, Miami, Milwaukee, Newport Beach, New York, Oklahoma City, Oxnard, Philadelphia, Portland, Providence, Rochester, Rock Hill, San Antonio, San Diego, San Francisco, Scottsdale, Southlake, Tacoma, Tampa, Tyler, West Monroe, Wichita
- Age
- 18 years and over
- People
- 1,092 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00 - Phase 3Taking peopleA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Anaheim, Atlanta, Carmel, Carrollton, Chapel Hill, Charlotte, Clive, Colorado Springs, Dothan, Farmington Hills, Glen Burnie, Hamden, Jacksonville, Lafayette, Lancaster, Los Alamitos, Los Angeles, Lubbock, Macon, Mentor, Miami, Mobile, Naples, New Bedford, New York, Northbrook, Oklahoma City, Orlando, San Antonio, San Diego, Shreveport, Summerville, Tampa, Topeka, Tyler, Uniontown
- Age
- 18 years and over
- People
- 530 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07499232 - Phase 3Taking peopleA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Anaheim, Chapel Hill, Chula Vista, Colorado Springs, Cordova, Crestview Hills, Farmington Hill, Lafayette, Lakewood Rch, Lee's Summit, Los Alamitos, Mentor, Metairie, Miami, New York, Oklahoma City, Orlando, Portland, Richmond, Rochester, San Diego, Scottsdale, Summerville, Sun City, Suwanee, Tacoma, Tampa, Tyler, Webster
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00 - Phase 4Taking peopleA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- Where
- Chapel Hill
- Age
- 18 years and over
- People
- 10
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07654751 - Phase 1/2Taking peopleAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- Where
- Bethesda
- Age
- 18 years to 65 years
- People
- 35
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
See details and how to joinNCT03167437 - Phase 2Taking peopleA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Where
- Atlanta, Bellaire, Clearwater, Dallas, Decatur, Fort Worth, Glen Burnie, Greenville, Iowa City, Kansas City, Kingwood, Lakeland, Las Vegas, Liberty, Louisville, Mansfield, Mentor, Miami Lakes, Murrieta, Naples, New York, Oklahoma City, Orange, Orlando, Providence, Rochester, San Antonio, Seattle, Tampa, Tyler
- Age
- 18 years to 75 years
- People
- 268 worldwide
- Run by
- Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00